Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease.

Health technology assessment (Winchester, England)

Volumn 7, Issue 3, 2003, Pages 1-67

  Clark, W ^a   Raftery, J ^b   Song, F ^b   Barton, P ^b   Cummins, C ^b   Fry Smith, A ^b   Burls, A ^b  

^a KEELE UNIVERSITY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY;

ADULT; COST BENEFIT ANALYSIS; CROHN DISEASE; DRUG COST; DRUG SCREENING; ECONOMICS; HUMAN; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; COST-BENEFIT ANALYSIS; CROHN DISEASE; DRUG COSTS; DRUG EVALUATION; HUMANS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84891587686     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta7030     Document Type: Review

References (92)